In the annual DART-filed results, revenue rose from KRW 370 million in 2022 to KRW 1.32 billion in 2023 (up 257.5% year on year), KRW 4.74 billion in 2024 (up 258.3%), and KRW 22 billion in 2025 (up 364.6%).
Revenue has increased for three consecutive years from 2023 through 2025, and 2025 was the largest year of 2022 to 2025.
Operating losses shrank each year, from KRW 4.61 billion in 2022 to KRW 4.02 billion in 2023, KRW 3.66 billion in 2024 and KRW 3.4 billion in 2025, and the company recorded losses for four consecutive years from 2022 to 2025. The operating margin improved from -1,245.4% in 2022 to -15.4% in 2025.
Net loss attributable to controlling shareholders widened to KRW 3.93 billion in 2025 from KRW 3.73 billion in 2024, and the net loss including non-controlling interests was KRW 4.12 billion in 2025.
At end-2025, total liabilities were KRW 56.4 billion and total equity was KRW 23.5 billion, so the debt-to-equity ratio reached 240.1%, up from 55.0% in 2024. Operating cash flow was negative every year: -KRW 4.1 billion in 2022, -KRW 2.82 billion in 2023, -KRW 5.96 billion in 2024 and -KRW 2.17 billion in 2025.
Quarterly, operating profit of KRW 169 million in Q3 2025 turned into an operating loss of KRW 848 million in Q4 2025, followed by a KRW 648 million operating loss in Q1 2026, an operating profit of KRW 406 million in Q2 2026, and an operating loss of KRW 190 million in Q3 2026.
Q3 2026 revenue was KRW 7.85 billion, up 3.4% from the prior quarter and 12.8% from a year earlier. The company's disclosed cumulative consolidated revenue for the first three quarters of 2026 was KRW 23.1 billion, up 68% year on year.
The company attributed the consolidated operating loss to higher R&D and investment costs at its cancer vaccine subsidiary and said the core business's profitability had not declined.
In Q1 2026, the net loss attributable to controlling shareholders of KRW 850 million exceeded the operating loss of KRW 648 million, so non-operating items had a larger effect. The company said first-half net income included convertible bond valuation gains and losses and interest expense, which are non-cash items.